Restricted accessLetterFirst published online 2012-12
Minor Fluctuations in Renal Function May Alter Therapeutic Drug Concentrations Substantially during High-Dose,Continuous-Infusion Beta-Lactam Therapy for Multi-Drug-Resistant Gram-Negative Bacilli
BariePS, HydoLJ, EachempatiSR. Causes and consequences of fever complicating critical surgical illness. Surg Infect, 2004; 5:145–159.
2.
EachempatiSR, HydoLJ, ShouJ, BariePS. The pathogen of ventilator-associated pneumonia does not influence the mortality rate of surgical intensive care unit patients treated with a rotational antibiotic system. Surg Infect, 2010; 11:13–20.
3.
CherryRA, EachempatiSR, HydoL, BariePS. Accuracy of short-duration creatinine clearance determinations in predicting 24-hour creatinine clearance in critically ill and injured patients. J Trauma, 2002; 53:267–271.
4.
HoVP, JenkinsSG, AfanehCIet al.Use of meropenem by continuous infusion to treat a patient with a bla(kpc-2)-positive Klebsiella pneumoniae blood stream infection. Surg Infect, 2011; 12:325–327.
5.
ZavasckiAP. Dose adjustment of polymyxins for renal insufficiency. Antimicrob Agents Chemother, 2011; 55:4940.
6.
PankeyGA, AshcraftDS. The detection of synergy between meropenem and polymyxin B against meropenem-resistant Acinetobacter baumannii using Etest and time–kill assay. Diagn Microbiol Infect Dis, 2009; 63:228–232.
7.
KvitkoCH, RigattoMH, MoroAL, ZavasckiAP. Polymyxin B versus other antimicrobials for the treatment of Pseudomonas aeruginosa bacteraemia. J Antimicrob Chemother, 2011; 66:175–179.
8.
ElkhailiH, NiedergangS, PompeiDet al.High-performance liquid chromatographic assay for meropenem in serum. J Chromatogr B Biomed Appl, 1996; 686:19–26.
9.
ObritschMD, FishDN, MacLarenR, JungR. Nosocomial infections due to multidrug-resistant Pseudomonas aeruginosa: Epidemiology and treatment options. Pharmacotherapy, 2005; 25:1353–1364.
10.
SchurekKN, SampaioJLM, KifferCRVet al.Involvement of pmrAB and phoPQ in polymyxin B adaptation and inducible resistance in non-cystic fibrosis clinical isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother, 2009; 53:4345–4351.
11.
SunHY, FujitaniS, QuintilianiR, YuVL. Pneumonia due to Pseudomonas aeruginosa II: Antimicrobial resistance, pharmacodynamic concepts, and antibiotic therapy. Chest, 2011; 139:1172–1185.
12.
SmythAR, BhattJ. Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis. Cochrane Database Syst Rev, 2012; 2:CD002009.
RobertsJA, WebbS, PatersonDet al.A systematic review on clinical benefits of continuous administration of beta-lactam antibiotics. Crit Care Med, 2009; 37:2071–2078.
15.
RiethmuellerJ, JungeS, SchroeterTWet al.Continuous vs. thrice-daily ceftazidime for elective intravenous antipseudomonal therapy in cystic fibrosis. Infection, 2009; 37:418–423.
16.
LorenteL, LorenzoL, MartinMMet al.Meropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to gram-negative bacilli. Ann Pharmacother, 2006; 40:219–223.
17.
KruegerWA, SchroederTH, HutchisonMet al.Pharmacokinetics of meropenem in critically ill patients with acute renal failure treated by continuous hemodiafiltration. Antimicrob Agents Chemother, 1998; 42:2421–2424.
18.
GilesLJ, JenningsAC, ThomsonAHet al.Pharmacokinetics of meropenem in intensive care unit patients receiving continuous veno-venous hemofiltration or hemodiafiltration. Crit Care Med, 2000; 28:632–637.
